To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Laboratory | Chemistry
Team LeaderDavide AUDISIOdavide.firstname.lastname@example.org
The discovery of new chemical reactions is a long-standinggoal of organic chemists. Recently, forced serendipity approaches have emerged as valuable alternative to purely rational approaches.
Over the last decade, we developed an unprecedented sandwich immunoassay screening which enables the high-throughput discovery and optimization of catalytic reactions.
This method, which allows the screening of more than 1000 catalysts or reaction conditions in a single day, has been successfully applied to new reaction discovery as well as asymmetric catalysis.
The development of chemical reactions that can be performed in living systems (i.e. cells, model organisms) has long held unique fascination in the field of chemical biology. A bio-orthogonal reaction is characterized by the reaction of two functionalities, which will react under mild physiological conditions and are inert towards the biological environment. Quintessential example is the copper-catalyzed azide-alkyne cycloadditions (CuAAC). We have recently applied the concept of chelation-assisted copper catalysis to the development of new azides that display unprecedented reactivity in the CuAAC, reacting almost instantaneously with alkynes under diluted conditions and in complex biological media.Driven by our in-house sandwich immunoassays high-throughput screening, we identified two new click reactions: the Copper-catalyzed Sydnone-Alkyne Cycloaddition (CuSAC) and the Strain-Promoted Sydnone-Alkyne Cycloaddition (SPSAC).
Carbon-14 isotopic labeling is a longstanding interest of our research group. Carbon-14 radiolabelling is a common procedure frequently used to understand the distribution, metabolism, toxicity of a drug in vivo, in pre-clinical and early clinical studies (Phase 0/1). As part of FDA’s safety assessment process, more than 80% of all drugs have used radioactive materials in their testing program.Our efforts in this field are focused on the development of new multi-step chemical procedures able to increase the labelling efficiency of biologically active molecule, as well as to reduce the production of radioactive waste. We are also actively involved in the development of new methodologies for 14C-labeling of nanoparticules and nanotubes in order to study their metabolism, in vivo biodistribution and toxicity.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.